Published in Hum Vaccin Immunother on January 01, 2014
Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany. Hum Vaccin Immunother (2015) 0.78
Attitudes of Dutch general practitioners towards vaccinating the elderly: less is more? BMC Fam Pract (2015) 0.75
Clinical and economic impact of herpes zoster vaccination in elderly in Italy. Hum Vaccin Immunother (2016) 0.75
Herpes zoster and the risk of ischemic and hemorrhagic stroke: A systematic review and meta-analysis. PLoS One (2017) 0.75
Analysis of Real-World Health Care Costs Among Immunocompetent Patients Aged 50 Years or Older With Herpes Zoster in the United States. Hum Vaccin Immunother (2017) 0.75
EQ-5D: a measure of health status from the EuroQol Group. Ann Med (2001) 18.69
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS. Proc R Soc Med (1965) 10.85
Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ (1996) 10.84
Varicella. Lancet (2006) 4.47
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis (2012) 3.94
Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ (2000) 3.40
Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm (2003) 3.34
Varicella-zoster virus. Clin Microbiol Rev (1996) 3.03
Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis (2005) 2.74
Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med (2010) 2.73
Postherpetic neuralgia. J R Coll Gen Pract (1975) 2.57
Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain (2002) 2.54
Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect (2008) 2.26
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis (2007) 2.19
Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain (2004) 2.15
Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis (2004) 2.14
The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain (2007) 2.08
Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine (2007) 2.01
Herpes zoster. BMJ (2007) 1.91
Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis (2011) 1.89
The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ (2010) 1.88
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med (2006) 1.74
The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine (2001) 1.72
Vaccination against Herpes Zoster and Postherpetic Neuralgia. J Infect Dis (2008) 1.70
The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health (2005) 1.57
A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol (2003) 1.55
Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine (2009) 1.55
Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis (2013) 1.54
Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain (2005) 1.53
Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol (2006) 1.40
Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis (2012) 1.36
The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin (2010) 1.32
Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine (2011) 1.31
Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review. PLoS One (2013) 1.17
The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000-2008. Epidemiol Infect (2011) 1.16
Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics (2007) 1.13
Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain (2007) 1.12
The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine (2011) 1.01
Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis (2007) 1.00
Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Intern Med (2011) 1.00
Proposed classification of herpes zoster pain. Lancet (1994) 0.99
Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting? Hum Vaccin Immunother (2013) 0.96
A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics (2013) 0.94
Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine (2013) 0.94
Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res (2013) 0.94
Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics (2009) 0.93
A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc (2010) 0.93
Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine (2011) 0.89
Safety of Zostavax™--a cohort study in a managed care organization. Vaccine (2012) 0.89
Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. Clin Infect Dis (2007) 0.89
Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res (2010) 0.89
Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother (2013) 0.87
FDA approves shingles vaccine: herpes zoster vaccine targets older adults. JAMA (2006) 0.85
Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin (2011) 0.85
Evidence of increasing frequency of herpes zoster management in Australian general practice since the introduction of a varicella vaccine. Med J Aust (2010) 0.83
Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? Vaccine (2011) 0.83
Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ (2010) 0.83
Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules. Hum Vaccin Immunother (2013) 0.82
Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol (2011) 3.13
Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health (2008) 2.31
Cost-effectiveness of pertussis booster vaccination in the Netherlands. Vaccine (2012) 2.00
Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics (2005) 1.71
Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations. Clin Ther (2010) 1.62
Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ (2005) 1.50
Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics (2008) 1.46
Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events. Br J Clin Pharmacol (2008) 1.39
GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis (2011) 1.22
The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges. Expert Rev Pharmacoecon Outcomes Res (2013) 1.19
Needle-free influenza vaccination. Lancet Infect Dis (2010) 1.13
Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Rev Vaccines (2008) 1.10
Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands. Clin Ther (2010) 1.09
Effectiveness and cost-effectiveness of a pharmacy-based screening programme for Chlamydia trachomatis in a high-risk health centre population in Amsterdam using mailed home-collected urine samples. Int J STD AIDS (2004) 1.05
Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence. Hum Vaccin Immunother (2013) 1.04
Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case. Eur Child Adolesc Psychiatry (2013) 1.03
Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands. BMC Infect Dis (2012) 1.01
Cost-effectiveness of HIV screening of blood donations in Accra (Ghana). Value Health (2008) 1.01
Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vaccines (2011) 0.99
[Dengue: a growing risk to travellers to tropical and sub-tropical regions]. Ned Tijdschr Geneeskd (2009) 0.99
Cancer incidence and mortality in Serbia 1999-2009. BMC Cancer (2013) 0.98
Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model. PLoS One (2010) 0.98
Impact of rotavirus vaccination on hospitalisations in Belgium: comparing model predictions with observed data. PLoS One (2013) 0.97
Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Am J Manag Care (2011) 0.96
Preventable hospital admissions related to medication (HARM): cost analysis of the HARM study. Value Health (2011) 0.96
Persistence with osteoporosis medication among newly-treated osteoporotic patients. J Bone Miner Metab (2013) 0.95
Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands. Clin Ther (2010) 0.95
Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health (2011) 0.95
Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics (2007) 0.94
Economic evaluations of hepatitis B vaccination for developing countries. Expert Rev Vaccines (2009) 0.94
Quantification of the potential impact of cost-effectiveness thresholds on dutch drug expenditures using retrospective analysis. Value Health (2010) 0.94
Mitigation of pandemic influenza: review of cost-effectiveness studies. Expert Rev Pharmacoecon Outcomes Res (2009) 0.94
Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine (2013) 0.94
Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J Infect Dis (2011) 0.93
Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis. BMJ (2012) 0.93
Systematic screening for Chlamydia trachomatis: estimating cost-effectiveness using dynamic modeling and Dutch data. Value Health (2006) 0.93
Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res (2011) 0.92
Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis. Respir Res (2014) 0.92
Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs (2012) 0.91
Direct medical costs of serious gastrointestinal ulcers among users of NSAIDs. Drugs Aging (2007) 0.91
Comparatively low attendance during Human Papillomavirus catch-up vaccination among teenage girls in the Netherlands: Insights from a behavioral survey among parents. BMC Public Health (2012) 0.91
Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination. PLoS One (2013) 0.90
Economic evaluation of folic acid food fortification in The Netherlands. Eur J Public Health (2008) 0.90
Further evidence for favorable cost-effectiveness of elderly influenza vaccination. Expert Rev Pharmacoecon Outcomes Res (2006) 0.90
Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther (2004) 0.89
Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries. Vaccine (2011) 0.89
Economic analysis of pandemic influenza mitigation strategies for five pandemic severity categories. BMC Public Health (2013) 0.88
Role of antibodies in controlling dengue virus infection. Immunobiology (2009) 0.88
Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective? PLoS One (2013) 0.88
The fiscal consequences of ADHD in Germany: a quantitative analysis based on differences in educational attainment and lifetime earnings. J Ment Health Policy Econ (2013) 0.88
Medication monitoring and optimization: a targeted pharmacist program for effective and cost-effective improvement of chronic therapy adherence. J Manag Care Spec Pharm (2014) 0.87
Human immunodeficiency virus prevalence, incidence, and residual transmission risk in first-time and repeat blood donations in Zimbabwe: implications on blood safety. Transfusion (2013) 0.86
Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy. Qual Life Res (2004) 0.86
Cost-benefit analysis of the detection of prescribing errors by hospital pharmacy staff. Drug Saf (2002) 0.86
Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases. Pharmacoeconomics (2004) 0.85
Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar). Vaccine (2010) 0.85
Economic evaluations of rotavirus immunization for developing countries: a review of the literature. Expert Rev Vaccines (2011) 0.85
Analyzing generic and branded substitution patterns in the Netherlands using prescription data. BMC Health Serv Res (2011) 0.85
A multicentre study of patient survival, disability, quality of life and cost of care: among patients with AIDS in northern Italy. Pharmacoeconomics (2004) 0.84
Health economics of blood transfusion safety--focus on sub-Saharan Africa. Biologicals (2009) 0.84
Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands. PLoS One (2013) 0.84
Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions. Expert Rev Vaccines (2012) 0.83
Impact of pharmacist recommendations on the cost of drug therapy in ICU patients at a Malaysian hospital. Pharm World Sci (2003) 0.83
Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands. Transfusion (2009) 0.83
Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. Value Health (2011) 0.83
Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs. Eur J Public Health (2009) 0.83
Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands. Appl Health Econ Health Policy (2005) 0.83
Economic evaluations of hepatitis A vaccination in middle-income countries. Expert Rev Vaccines (2013) 0.83
Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther (2003) 0.83
On discounting of health gains from human papillomavirus vaccination: effects of different approaches. Value Health (2012) 0.83
Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review. J Antimicrob Chemother (2013) 0.82
Cost-effectiveness of rotavirus immunization in Indonesia: taking breastfeeding patterns into account. Vaccine (2013) 0.82
Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. Pharmacogenet Genomics (2009) 0.82
Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness? Expert Rev Pharmacoecon Outcomes Res (2004) 0.82
Modelling the impact of chlamydia screening on the transmission of HIV among men who have sex with men. BMC Infect Dis (2013) 0.82
Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. Pharmacoeconomics (2008) 0.81
Sexually transmitted infections screening at HIV treatment centers for MSM can be cost-effective. AIDS (2013) 0.81
Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes. J Med Econ (2008) 0.81
A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands. Clin Ther (2003) 0.81
Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making. Pharmacoeconomics (2006) 0.81
Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation. Vaccine (2013) 0.81
Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. Cost Eff Resour Alloc (2007) 0.81
Direct costs of hypertensive patients admitted to hospital in Vietnam- a bottom-up micro-costing analysis. BMC Health Serv Res (2014) 0.80
The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine. Pharmacoeconomics (2005) 0.80
[Influenza vaccination of hospital healthcare staff from the perspective of the employer: a positive balance]. Ned Tijdschr Geneeskd (2010) 0.79
Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence. Pharmacoeconomics (2011) 0.79
Economics of assisted reproduction: access to fertility treatments and valuing live births in economic terms. Hum Fertil (Camb) (2010) 0.79
Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands. Clin Ther (2010) 0.79
Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban. Expert Rev Pharmacoecon Outcomes Res (2007) 0.79
The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective. Expert Rev Vaccines (2014) 0.79